Immuno-Oncology Research

The immune system contains powerful mechanisms to fight cancer, and immuno-oncology research helps us understand that potential. Global genomic mutations that disrupt normal cellular function can lead to unchecked growth and cancer, often producing novel proteins in the process. These potentially immunogenic proteins present a unique treatment opportunity through immune effector cell recruitment.

Microsatellite Instability

MSI has become an increasingly relevant tool in genetic and immuno-oncology research. Deficiencies in mismatch repair caused by germline mutations or hypermethylation can lead to the accumulation of transcription errors in microsatellite sequences.

PCR-Based MSI Detection

Explore our microsatellite instability testing solutions, available for both research and diagnostic use (in certain countries).

The History of MSI Research

Dr. James Eshleman is an expert in microsatellite instability. Watch the talk he gave at AMP 2017.

The Evolution of MSI Detection

Promega scientist Jeff Bacher has worked on MSI detection methods for two decades. Read the story of how modern MSI detection methods were developed.

DNA Purification

The first step in MSI analysis is nucleic acid purification. Successful downstream assays, including PCR-based MSI detection, require pure, amplifiable DNA.

ccfDNA 101: Emerging Trends in Oncology Research

In this webinar, Promega scientist Doug White discusses ccfDNA and its importance to oncology research.

To NanoDrop or Not To NanoDrop?

In this webinar, Promega scientist Jennifer Mook discusses finding the most appropriate method for nucleic acid quantitation.

Biologics and Drug Discovery

Programmed Cell Death Protein 1 (PD-1) is just one example of a target for immune checkpoint blockade. Blocking the interaction of PD-1 with either of its ligands (PD-L1 or PD-L2) can lead to activation of the T cell receptor (TCR), which can encourage an immune response. Immune checkpoint receptor bioassays reflect the mechanism of action of biologics designed to block these interactions.

Immune Checkpoint Bioassays

In this webinar, Dr. Richard Somberg discusses MOA-based functional bioassays for antibody screening, characterization, potency testing and stability studies.

Has Cancer Met Its Match?

Promega blogger Kari Kenefick wrote about emerging immune checkpoint inhibitors and their promises for cancer treatment.

PD-1+TIGIT Combination Bioassay

The bioluminescent PD-1+TIGIT Combination Bioassay reflects the MOA of biologics designed to target both PD‑1 and TIGIT.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

In 2015, Le et al. demonstrated that MSI-H tumors respond particularly well to immune checkpoint blockade. This groundbreaking paper brought MSI into the spotlight in immunotherapy research.

Read the Paper

Let's find the solution that meets your needs.

Talk to a Scientist

Promega's Cookie Policy